Dopamine receptors are members of a large superfamily of receptor proteins coupled to heterotrimeric guanine nucleotide-binding regulatory proteins (G proteins). They are involved in motor control, neuroendocrine regulation, cognition and emotion. These receptors are crucial targets in the therapy of schizophrenia, Parkinson's disease, Tourette's syndrome, tardive dyskinesia and Huntington's disease (1).
rated by alternative splicing from the same gene. They differ by an in-frame insert of 29 amino acids specific to D 2L within the third cytoplasmic loop of the receptor (4) . Expression of two isoforms is tissue-specific (5), D 2L appearing to be the major isoform (6, 7) . Analysis with subtype-specific antibodies against both the D 2S and long isoforms have shown a unique compartmentalization between these two isoforms in the primate brain. Splice variants of the dopamine D 2 receptor are differentially distributed and possess distinct functions. The strategic localization of the D 2S isoform in dopaminergic cell bodies and axons strongly suggests that this isoform is the likely dopamine autoreceptor, whereas the D 2L isoform is primarily a postsynaptic receptor (8) .
D 1 receptors activate adenylyl cyclase and are coupled to Gs regulatory protein. In contrast, activation of D 2 receptors results in various responses including inhibition of adenylyl cyclase and phosphatidylinositol turnover, increase in K + channel activity and inhibition of Ca 2+ mobilization (6) . All these different signalling pathways involve the activation of the Gi/Go family of G proteins (7, 9) . First, G i2 appeared to couple selectively to the D 2 receptor with ∼10-fold higher affinity than any other tested Gi subtype (10) . Later, the same authors have shown that alternative splice forms of D 2 dopamine receptor are able to signal to different Gi proteins (11) . Specifically, it seems that 29 amino acid insert of D 2L confers interaction selectivity for G i2 (4) . Preferential interaction of the D 2S isoform with G i1 than G i2 was demonstrated (7) that was consistent with previous results. Using different experimental approach other authors demonstrated an essential difference in coupling of dopamine D 2L and D 2S receptors to G proteins (12, 13) . As the two forms of dopamine D 2 receptors differ within the third cytoplasmic loop, the data presented support the data on the importance of this domain in receptor coupling to G proteins, as well as the functional significance of the 29-amino acid insert in the third loop of D 2L (4) . Comparison of the D 2 receptor gene in humans and mice demonstrates that its sequence and splicing events have been highly conserved through the evolution. This might indicate that the presence of the two isoforms and their selective interaction with different G proteins represent an essential feature of the dopamine D 2 receptor function in vivo (4).
Cerebral D 2 dopamine receptor is the target for pharmaceuticals used to alleviate the main symptoms of schizophrenia and seems to play an essential role in the dopaminergic control of physiological functions (14) . All currently used antipsychotic agents have antidopaminergic properties, but the side effects associated with their use suggest that therapeutic alternatives are necessary (15) . Compounds that interact directly with G proteins can mimic the receptor/G protein interaction or can block the activation of G proteins by receptors (16) . To date, virtually all known antagonists of these receptors share the common property of blocking access of the ligand to the receptor. Alternative strategy for designing receptor antagonists might be to block the interaction of the receptor with the G protein (17) . The third intracellular domain (3i) of G protein coupled receptors plays a major role in the activation of G proteins. Alterations in this region of the receptor can affect receptor/G protein coupling efficiency and specificity. Coexpression of the 3i loop with its homologous receptor resulted in specific inhibition of agonist-stimulated second messenger generation mediated via homologous receptor (17) . This suggests that peptides derived from a G protein-coupled receptor might serve as antagonists of receptor/G protein interactions (18) . Inhibition could occur by several mechanisms, such as competition for Ga subunits of a hormone-receptor complex and the free 3i loop of the receptor, or interaction between the 3i loop peptide and the intracellular domains of the parent receptor thus disrupting receptor conformation and keeping it inactive (17) . The finding that: a) the 3i domain peptide provoked inhibition of homologous receptor signalling was surmountable at high receptor density and b) that weak enhancement of basal second messenger generation in cells expressing the 3i domain alone is detected (18) led to conclusion that 3i domain peptides act as weak partial agonists at the level of the G protein. Partial DA-receptor agonists should be eminently suitable for stabilizing neurotransmitter function. Such agents can also be described as mixed agonist-antagonists, implying that they serve as an agonist when the level of endogenous full agonist is low at receptor sites and as an antagonist when this level is high (15) . The specificity with which the 3i domain peptides inhibit receptor-mediated signalling suggests the feasibility of developing drugs that might exert inhibition at the level of receptor/G protein interaction rather than at the level of ligand-receptor binding (18) . Therefore, finding domains essential for this interaction could be of great significance in future design of pharmacologically active compounds.
Materials and methods
Plasmid DNA encoding hD 2L CPL3 (pCD3hD-2lPDX) was kindly donated by Dr. O. Civelli (Oregon Health Sci. Univ., Portland, OR, U.S.A.). Plasmid pQE-60, encoding G i a1 , was a generous gift of Dr Christiane Kleuss (Freie Unive. Berlin, Inst. Pharmacol., Berlin, Germany). Plasmids encoding fragments of D 2L -CPL3 cloned into pGEX-2T (fr1: 211-241. a.a., fr3-211-277. a.a. and fr4-271-373. a.a.) were previously constructed in our laboratory by Ms Marija Backovi} and Ms Bosiljka Tasi} (data not published).
The other materials were obtained from the following commercial sources: expression vector pGEX-2T, restriction endonucleases, T4 DNA ligase, alkaline phosphatase and T4 polynucleotide kinase ' BiolabsNew England, U.S.A.; PfuDNA polymerase ' Stratagene, La Jolla, CA, U.S.A.; DNAse ' Boehringer, Man-cheim, Germany; ATP, GDP, phenylmethylsulfonylfluoride (PMSF), ampicillin ' Sigma Chem.Co., St. Louis, MO, U.S.A.; glutathione (GSH) and Na-deoxycholate ' Merck, Darmstadt, Germany; Glutathione-Sepharose ' Pharmacia LKB, Uppsala, Sweden; bactopeptone, yeast extract and bacto agar ' Difco Laboratories, Detroit, MI, U.S.A.; CDNB ' Squib-Bristol. All other chemicals were of analytical grade of purity.
Cloning of the insert of the third intracellular loop of the human dopamine D 2L receptor into pGEX-2T ' Standard molecular biology procedures were used for DNA manipulations (19) . The insert of the CPL3 of the hD 2L receptor was amplified by polymerase chain reaction (PCR). To obtain insert of the CPL3-D 2L the following pair of primers was used in PCR containing plasmid DNA encoding hD 2L CPL3 as a template: forward-5'-GCGC GGA TCC CAC CTG AGG GCT CCA CTA AAG-3' and reverse-5'-GCCG GAA TTC CTG GGC TCG CCG GGC AGC CTC-3'. The PCR product was cut with BamHI and EcoRI restriction enzymes and cloned into BamHI-EcoRI sites of the prokaryotic expression plasmid pGEX-2T. The validity of the DNA constructs was confirmed by automated fluorescent DNA sequencing using reagents and instruments from Applied Biosystems (California, USA).
Expression and purification of the D 2L -CPL3
fragment fusion proteins ' E. Coli BL21 was maintained and transformed with pGEX-2T-D 2L -CPL3 fragment using CaCl 2 method (19) . The cells were grown in LB medium supplemented with ampicillin and expression was induced with iso-propylthiogalactoside (IPTG) as described by Simonovi} et al. (20, 21) . D 2L -CPL3 fragment-GST fusion proteins were purified using GSH-Sepharose (20, 21) .
Expression and purification of His-Ga protein
' This was done as described by Lee et al. (22) .
Ga-D 2L -CPL3 fragments-GST His-Bind Resin
Assay ' This was performed as suggested by Simonovi} et al. (20) .
Assay for detection of D 2L -CPL3 fragment-Ga complexes on SDS-PAGE ' Glutathione-Sepharose
Resin was washed with buffer (10 mmol/L Tris, pH-7.4, 0.1% BSA) by repeated centrifugation (1000 rpm, 1 min) and 10 mg of each GST-fusion protein in the same buffer (total volume ∼90 mL) was loaded onto ∼40 mL of equilibrated 50% resin suspension. The resin was incubated (30 min, 22 °C, constant shaking), double washed with ice-cold buffer, to remove unbound proteins. G i a 1 solution (20 mg, in ∼90 mL of buffer containing 10 mmol/L Tris-HCl, pH 7.4, 0.1% BSA, 1.0 mmol/L GDP and 5 mmol/L MgCl 2 ) was added and the incubation continued for 60 min. Unbound protein was removed by successive washing with icecold buffer (10 mmol/L Tris-HCl, pH 7.4, 120 mmol/L NaCl; 0.1% Triton X-100). The agarose beads were boiled in sample buffer, subjected to SDS/PAGE and the gel was silver stained (23) . The controls containing only Ga without GST-CPL3 fragment and only GST-CPL3 fragment without Ga, served to distinguish binding of Ga to CPL3 fragment from non-specific binding of Ga to the resin.
Data analysis ' Saturation binding data were analyzed and graphically displayed by one site binding curve fitting using the Micorcal Origin 6.0 program which was also employed to calculate Kd values.
Miscellaneous ' Proteins were determined after Bradford et al. (24) using bovine serum albumin (BSA) as a reference. Degree of protein purification was checked by SDS-PAGE as described by Laemmli (25) . The appearance of the band representing G i a 1 on SDS-PAGE slab gel ( Figure 5 ) was an alternative proof for the interaction of the Ga subunit with all four fragments of D 2L -CPL3 examined in the present study.
Results

Four
Discussion
Several authors used a strategy of coexpression of peptides from D 2L -CPL3 with its homologous receptor in vivo (26, 27) and showed that regions flanking each extremity of the loop are fundamental for coupling of the receptor to G proteins. Insert in the long form of the dopamine D 2 receptor doesn't seem to affect functional coupling of the D 2L receptor to G protein (26) , but plays a critical role in the selectivity of these interactions (4). Since it is located outside the regions responsible for interactions with G protein, it was hypothesized that it might affect coupling specificity indirectly by incorporating novel stretch of residues in CPL3 and thus interrupting a putative ahelical structure, generating a novel structure that confers interaction selectivity for G i a 2 (4) . Quantitative estimation of these interactions hasn't been performed previously.
Our results are in accordance with the data of several authors (26, 27) demonstrating that the NH 2 -and COOH-terminal portions of the third cytoplasmic loop of the dopamine D 2 receptor do interact directly with a subunit of G protein. Further, we showed that there is no particular domain in the D 2L -CPL3 responsible for this interaction, as judged by a high affinity binding of all fragments except one, representing the insert in the long form of the D 2 receptor, which also interacts with Ga, but with about 10-fold lower binding affinity. This high binding affinity suggests that selectivity was achieved by direct contact of insert with G protein rather than inducing changes in conformation of other parts of CPL3.
The identification of domains crucial for the in- teraction with G protein, and qualitative and quantitative estimation of these interactions could be useful in developing new therapeutic agents that would behave as weak partial agonists at the level of receptor/G protein interaction. However, peptides themselves are unlikely to be suitable as therapeutics because of problems with peptidases and inability to penetrate through target cell membrane. Solutions to these problems might be found in the synthesis of peptidomimetics ' non-peptide analogues of similar structure that could mimic peptide activities or introduction of these domains to target cells by gene therapy (28) . (1) 13 Figure 5 . SDS-PAGE analyses of interactions of GST-fusion proteins with G i a1 -His-GDP. As standard we used 10 kDa Protein Ladder (Gibco BLR). Gel was silver stained. Kratak sadr`aj: U cilju pronala`enja bitnih strukturnih motiva potrebnih za interakciju sa a podjedinicom G i1 proteina klonirana su, eksprimirana i pre~i{}ena 4 fragmenta tre}e citoplazmati~ne petlje (CPL3) dopaminskog D 2L receptora koji su dalje pripremljeni kao fuzioni proteini sa glutation-S-transferazom (GST). Interakcije su kvantifikovane bojenom reakcijom za odre|ivanje aktivnosti GST. Postojanje kompleksa D2L-CPL3 fragment-G i a 1 je dokazano elektroforetskom analizom na SDS-poliakrilamidnom gelu (PAGE). Kd vrednosti za tri fragmenta su bile vrlo sli~ne i u nmol/L opsegu koncentracija, dok je peptid koji predstavlja insert u dugom obliku dopaminskog D 2 receptora posedovao oko 10 puta manji afinitet vezivanja za G i a 1 . Ovi rezultati mogu biti osnova za sintezu novih terapeutskih agenasa koji bi delovali na nivou interakcije receptora i G proteina umesto na nivou vezivanja liganda za receptor.
Klju~ne re~i: dopaminski D 2L receptor, tre}a intracelularna petlja, sintetski peptid, sprega receptor/G protein.
